LaxmanBhagwanBahrooDOFAAN

PubMed

• Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease.
  Abhishek Lenka, Gianluca Di Maria, Guillaume Lamotte, Laxman Bahroo, Joseph Jankovic> ;Expert Review of Neurotherapeutics. 2022 Jun 1
• AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
  Mark F. Lew, Robert A. Hauser, Stuart Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William G. Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman B. Bahr...> ;Clinical Parkinsonism & Related Disorders. 2021 Jan 1
• 10 citations
  Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study.
  Atul T. Patel, Theodore Wein, Laxman B. Bahroo, Ophélie Wilczynski, Carl Rios, Manuel Murie-Fernandez> ;JMIR Public Health and Surveillance. 2020 Dec 7
• 2 citations
  AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles
  Khashayar Dashtipour, Stefan Wietek, Bruce Rubin, Pascal Maisonobe, Laxman B. Bahroo, Richard Trosch> ;Journal of Clinical Movement Disorders. 2020 Aug 31
• 1 citations
  Keeping up with the clinical advances: tardive dyskinesia.
  Mazen T. Elkurd, Laxman Bahroo> ;CNS Spectrums. 2019 Aug 1
• 11 citations
  The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
  Mazen T. Elkurd, Laxman Bahroo, Rajesh Pahwa> ;Neurodegenerative Disease Management. 2018 Mar 22
• 28 citations
  Botulinum Toxin Injection Techniques for the Management of Adult Spasticity
  Heather W. Walker, Michael Y. Lee, Laxman B. Bahroo, Peter Hedera, David Charles> ;PM & R. 2015 Apr 1
• 19 citations
  An update on the use of botulinum toxin therapy in Parkinson's disease.
  Reversa Mills, Laxman B. Bahroo, Fernando Pagan> ;Current Neurology and Neuroscience Reports. 2015 Jan 1
• Join now to see all

Journal Articles

• Approach to the management of psychosis in Parkinson’s Disease  
  Lenka A, Gomathinayagam V, Bahroo L, Annals of Movement Disorders, 9/2019
• Hyperkinetic Movement Disorders  
  Farzal Z, Lamotte G, Bahroo L, Practical Neurology, 9/2019
• Parkinson’s Disease Treatment Update  
  Farzal Z, Lamotte G, Bahroo L., Practical Neurology, 9/2019
• Anterocollis posture and deep cervical muscle injections with BoNT.  
  Bahroo L, Toxicon, 1/2019
• Anti-Alpha-Synuclein Therapies in Parkinson’s Disease  
  Elkurd M, Torres-Yaghi Y, Bahroo L, Moussa C, Pagan, F., Practical Neurology, 9/2018
• Tardive Dyskinesia: A New Treatment for an old Disorder  
  Bahroo L, Gandhy R, Practical Neurology, 6/2017
• New and Emerging Therapies in Parkinson's Disease  
  Bahroo, L; Amjad, F; Dashtipour, K; Pagan, F, Practical Neurology, 4/2016
• Spastic Paresis and Rehabilitation - A Patient Journey ropean Neurological Review -2016;11(2):87–95  
  Bowers D, Federoff K, Khan P, Harriss J, Dashtipour K, Bahroo L, Lee M, Zakharov D, Balcaitiene J, Evidente V., European Neurological Review, 2016
• Botulinum Toxin Injection Techniques for the Management of Adult Spasticity  
  Walker H, Lee MY, Bahroo L, Hedera P, Charles D, PM R, 1/1/2015
• Behind the masked face: depression and Parkinson's disease  
  Bahroo L, Appleby B, Minerva Psichiatrica, 1/1/2009
• Join now to see all

Books/Book Chapters

• Encyclopedia of Movement Disorders 
  Bahroo L, Shamin EEditors: Kompoliti K and Verhagen L.Elsevier2010

Abstracts/Posters

• BoNT/A immunogenicity: a systematic review of the literature.
  Lacroix-Desmazes S, Colosimo C, Bahroo L, International Neurotoxin Association Conference, Lisbon, Portugal, 1/14/2015
• Analyzing the Patient Journey for Patients Living with Spastic Paresis.
  Bowers D, Khan P, Dashtipour K, Bahroo L, Lee M.Y. Balcaitiene J, Evidente V, Academy of Physical Medical & Rehabilitation Annual Assembly, Boston, MA, 1/1/2015
• Analysis of Abobotulinum toxin A Seroconversion in Cervical Dystonia and Spasticity.
  Landen A, Bahroo L, International Neurotoxin Association Conference, Miami Beach, FL, 1/5/2012
• A "Real World" view of the tolerability of Rasagiline with Anti-depressants in Parkinson's Disease: A retrospective study.
  Chhabria N, Ghosh P, Bahroo L, Pagan, F, 63th Annual American Academy of Neurology Meeting, Honolulu, HI, 1/9/2011
• The tolerability of rasagiline and concurrent serotonin reuptake inhibitors in Parkinson's disease: A retrospective study.
  Ghosh P, Winslow J, Musleh C, Gandhy C, Bahroo L, Pagan, F, 14th International Congress of Parkinson's disease and Movement Disorders, 1/5/2010
• Join now to see all

Lectures

• The Spasticity and Movement Disorders IMPACT Initiative CME program 
  Washington D.C - 1/11/2020
• Medication Induced Movement Disorders, Neurotoxin Education Institute (NEI) Congress 
  Colorado Springs, CO - 11/2019
• Neurotoxin Education Series 
  Web based - 6/2019
• Off time in Parkinson’s Disease Controversies in Neurology (CONy) 
  Madrid, Spain - 5/2019
• Tardive Dyskinesia (Pro position) Controversies in Neurology (CONy) 2019 
  Madrid, Spain - 4/2019
• Anterocollis Posture and Deep Cervical Muscle Injections with BoNT, International Neurotoxin Association 
  Copenhagen, Denmark - 1/2019
• Tardive Dyskinesia, Neurotoxin Education Institute (NEI) Congress 
  Orlando, FL - 11/2018
• Update in Focal Dystonia 
  Multiple Locations, 2012, 2013, 2014, 2015 - 1/1/2015
• Scientific update on Botulinum Toxins 
  Columbus, OH, 2015; Washington, DC, 2015 - 1/1/2015
• Cleveland Clinic Headache and Neurotoxin Update 
  Cleveland, OH - 1/1/2013
• Update in Neurology Therapeutics 
  Georgetown University Hospital, 2011, 2012 - 1/1/2012
• PA in Primary Care 
  1/1/2011
• Parkinson's Disease and Multiple Sclerosis Update for Neurologists 
  1/1/2011
• Update in Neurological Therapeutics 
  Georgetown University Hospital - 1/1/2010
• Join now to see all